Emory University’s Travere Therapeutics TVTX Stock Holding History

Emory University’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-77,180	Closed	-$895K	–	11
2019 Q3	$895K	Sell	77,180 -46,420	-38%	-$767K	1.76%	13
2019 Q2	$2.48M	Buy	123,600 +12,973	+12%	+$256K	1.75%	13
2019 Q1	$2.5M	Buy	110,627 +17,687	+19%	+$391K	1.76%	13
2018 Q4	$2.1M	Sell	92,940 -4,570	-5%	-$114K	1.66%	18
2018 Q3	$2.8M	Buy	+97,510	New	+$2.79M	1.83%	15
2018 Q2	–	Sell	-115,136	Closed	-$2.57M	–	49
2018 Q1	$2.57M	Buy	115,136 +30,251	+36%	+$720K	1.84%	14
2017 Q4	$1.79M	Buy	84,885 +10,968	+15%	+$251K	1.54%	32
2017 Q3	$1.84M	Sell	73,917 -17,191	-19%	-$379K	1.46%	18
2017 Q2	$1.77M	Buy	+91,108	New	+$1.65M	1.56%	9

Other funds holding TVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Emory University's TVTX Position: Q4 2019 in Review

Emory University sold out of Travere Therapeutics (TVTX) in Q4 2019, closing a stake of 77,180 shares — an estimated $895K sold.

Emory University first reported a position in TVTX in Q2 2017 and held it in 9 quarters. The position peaked at $2.8M in Q3 2018. 131 funds tracked by Wall St. Rank hold TVTX as of Q4 2019.

Emory University reported no remaining Travere Therapeutics position as of Q4 2019 after selling out during the quarter.
Emory University sold 77,180 Travere Therapeutics shares in Q4 2019, an estimated $895K.
Emory University first reported a position in Travere Therapeutics in Q2 2017 and held it in 9 quarters.
Emory University's Travere Therapeutics position peaked at $2.8M in Q3 2018.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2019.

Based on Emory University's 13F filing for Q4 2019, filed 13 Feb 2020.